Effect of oral nimodipine on platelet function

Area of Science:

• Pharmacology
• Cardiovascular Research
• Hematology

Background:

• Nimodipine, a calcium antagonist, is known for its effects in acute ischemic infarction.
• Calcium channel antagonists may possess antiplatelet properties.
• The antiplatelet potential of oral nimodipine requires investigation.

Purpose of the Study:

• To evaluate the impact of oral nimodipine on platelet function in healthy individuals.
• To determine if nimodipine exhibits antiplatelet activity at therapeutic doses.

Main Methods:

• A randomized controlled study involving 12 healthy volunteers.
• Administration of oral nimodipine at 30 mg and 60 mg doses every 6 hours.
• Ex vivo assessment of platelet aggregation, adenosine triphosphate release, and thromboxane B2 levels.
• Measurement of bleeding times.

Main Results:

• No significant alterations in platelet function were observed with 30 mg nimodipine.
• The 60 mg dose showed a minor reduction in adenosine triphosphate release and aggregation in response to adenosine diphosphate.
• No significant changes in bleeding times were recorded.

Conclusions:

• Oral nimodipine demonstrates minimal antiplatelet activity in young, healthy subjects.
• The observed effects on platelet function are not clinically significant at the tested dosages.